Health Doctor Health updates

Precision Optics Reports Third Quarter Fiscal Year 2021 Financial Results

Precision Optics Reports Third Quarter Fiscal Year 2021 Financial Results

GARDNER, Mass., May 13, 2021 Precision Optics Corporation, Inc. (OTCQB: PEYE), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its third quarter fiscal year ended March 31, 2021.

Third quarter fiscal 2021 highlights:

  • Revenue for the quarter ended March 31, 2021 was $2.46 million compared to $2.37 million in the same quarter of the previous fiscal year.

  • Gross margins for the quarter ended March 31, 2021 were 33% compared to 34% in the same quarter of the previous fiscal year; and compared to 31% for the quarter ended December 31, 2020.

  • Net Income of $552,280 during the quarter included $809,000 of Other Income due to the forgiveness of the SBA PPP Loan as well as $86,000 of stock-based compensation. This compared to a loss of $466,000, including $76,000 of stock-based compensation in the same quarter of the previous fiscal year.

  • The Company’s cash position remains strong with an ending balance for the third quarter of $782,000.

Precision Optics’ CEO, Joseph Forkey, commented, “The market opportunity for micro-optic and 3D-enabled devices and components in the medical and defense industries continues to be robust. Large, established industry players, and well-funded startup companies are looking for enabling technology partners, such as Precision Optics, that can make next generation products a reality. Over the past couple of years, we have made significant progress expanding the number of jointly developed projects in our engineering pipeline.  We expect many of these to move into production in the coming year to help drive growth.”

Dr. Forkey continued, “While our ongoing production levels continue to be depressed due to the pandemic, the increase in engineering pipeline activity has helped to cushion the impact on overall revenues.  Our production revenue of $1.9 million during the quarter was flat compared to the most recent quarter and was down about $250,000 from the third quarter a year ago. Engineering revenue of $550,000 was down sequentially, but was up year-over-year, and is expected to increase again in future quarters.  Due to revenue recognition timing, reported revenue growth quarter-to-quarter may not reflect the full underlying growth trend of the business.  Further, we have efficiently managed the business with year-to-date improvements in adjusted EBITDA of over $500,000 compared to the same period a year ago. With a burgeoning pipeline, near-term projects expected to move from the pipeline to production, and the resumption of normalized production levels for products impacted by the pandemic, we believe we are well positioned heading into fiscal 2022.”

About Precision Optics Corporation

Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and 3D imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture.  Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division’s high volume world-wide sourcing, inspecting and production resources, the Precision Optics is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power.

About Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company’s future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by the Company’s management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company’s annual report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement, except as required by law.

Disclaimer: The following Press Release comes to you under a network of a strategic syndication partnership with PR Newswire. Prittle Prattle News takes no editorial responsibility for the same.

Media of the day

Skip to toolbar